Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Cerus Corporation ($CERS) stock perked up as the company announced inking deal with the Central California Blood Center. The new deal pertains to the company’s INTERCEPT plasma. The Center will use the plasma for manufacturing pathogen-reduced cryoprecipitate, to control bleeding in patients with acquired fibrinogen deficiency. The company is looking to file a regulatory application seeking approval for a five-day post-thaw claim. Cryoprecipitate is recognized as an important source of fibrinogen replacement for these bleeding patients.
The company stock gained over 10 percent in its previous trading session, trimming its Year to Date losses to 44 percent.

Interpace Diagnostics ($IDXG) announced that its ThyGenX molecular test is now covered by health insurer Cigna. The test is used to assess more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. The test is already covered by Aetna, Medicare, United Healthcare and other payers. With Cigna on board, the total number of covered lives for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules stands at approximately 275 million patients nationwide.
The company stock reacted positively to the news and jumped up in the stock market.


Cytokinetics ($CYTK) announced commencing a Phase 2 clinical trial testing its fast muscle troponin activator, CK-2127107, in patients with amyotrophic lateral sclerosis. The study will measure the change from baseline in a measure of lung function called percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment.

VBI Vaccine ($VBIV) announced that the preliminary data from a Phase 1 clinical trial assessing preventative cytomegalovirus (CMV) vaccine, VBI-1501A, showed encouraging action. The data showed that the vaccine was well tolerated at all doses with no safety signals observed. It induced antibody responses in a dose-related manner, with the highest dose stimulating seroconversion in all subjects after two vaccinations.

Trovagene ($TROV) announced that the FDA has accepted its Investigational New Drug (IND) application seeking authorization to initiate clinical studies assessing PLK1 inhibitor PCM-075 for the treatment of acute myeloid leukemia.

AstraZeneca ($AZN) announced that its open-label Phase 3 MYSTIC study assessing Imfinzi (durvalumab), in combination with tremelimumab, compared to platinum-based chemo in a first-line setting in patients with metastatic non-small cell lung cancer (NSCLC) failed to achieve its primary endpoint.


Tesaro ($TSRO) announced inking an exclusive licensing deal with Takeda Pharmaceuticals Company. The deal allows Takeda to develop and commercialize the PARP inhibitor for all tumor types in Japan and all tumor types except prostate cancer in South Korea, Taiwan, Russia and Australia. Tesaro will be entitled to receive $100 million upfront and up to $240M in milestones and tiered double-digit royalties on net sales.

Alexion Pharmaceuticals ($ALXN) announced that it has sent a written notice to Arbutus Biopharma regarding the termination of their March 2017 LNP license agreement. The company took the decision after completing a strategic review of its business and R&D portfolio, including a decision to discontinue development of mRNA therapeutics.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Stifel Nicolaus Reiterates Acorda Therapeutics (ACOR)
Buy Low

Stifel Nicolaus Reiterates Aerie Pharmaceuticals (AERI)
Buy $70.00 Low

Cowen and Company Reiterates Astrazeneca PLC (AZN)
Hold $34.00 Low

Cowen and Company Reiterates Boston Scientific Corporation (BSX)
Buy $32.00 Low

Stifel Nicolaus Reiterates Cerner Corporation (CERN)
Hold $69.00 Low

Stifel Nicolaus Reiterates Innoviva (INVA)
Hold $15.00 Low

Cowen and Company Reiterates Innoviva (INVA)
Buy $16.00 Low

Commerzbank Ag Reiterates Qiagen N.V. (QGEN)
Buy Low

Cowen and Company Reiterates Seattle Genetics (SGEN)
Hold $54.00 Low

Gainers (% price change)Last TradeChangeMkt CapCerus CorporationCERS2.40+0.22 (10.09%)251.66MAnika Therapeutics IncANIK51.70+3.71 (7.73%)757.64MMerit Medical SystemsMMSI40.70+2.90 (7.67%)2.03BClovis Oncology IncCLVS92.25+4.82 (5.51%)4.44BCompugen Ltd. (USA)CGEN4.05+0.15 (3.85%)196.03MLosers (% price change)AstraZeneca plc (ADR)AZN28.88-5.06 (-14.91%)71.72BCommunity Health SystemsCYH7.23-1.23 (-14.54%)829.21MDynavax Tech. Corp.DVAX9.25-1.15 (-11.06%)506.42MClearfield IncCLFD12.40-1.40 (-10.14%)174.77MDr.Reddy's LaboratoriesRDY38.30-3.37 (-8.09%)6.42BMost Actives (dollar volume)Merck & Co., Inc.MRK63.69+1.89 (3.06%)174.20BBristol-Myers Squibb CoBMY54.24-1.74 (-3.11%)89.36BGilead Sciences, Inc.GILD74.96+0.77 (1.04%)97.95BAmgen, Inc.AMGN172.15-3.74 (-2.13%)126.60BCelgene CorporationCELG134.15-3.60 (-2.61%)104.75B